Mr. Peter Bakema reports

CVR MEDICAL ANNOUNCES CLOSING OF FINAL TRANCHE OF FINANCING

CVR Medical Corp. has closed the final tranche of its previously announced non-brokered private placement financing.

An aggregate of 1,710,395 units at a price of 40 cents per unit were issued in the final tranche for gross proceeds of $684,158.

Proceeds from the financing will be used for continuing working capital requirements relating to the joint venture described below, specifically in regard to Food and Drug Administration applications and clinical trials.

Each unit consists of one common share of CVR Medical and one-half of one transferable common share purchase warrant. Each warrant is exercisable at a price of 70 cents until June 18, 2019.

In the final tranche closing, CVR Medical paid finders' fees of 6 per cent cash and 6 per cent compensation warrants comprising a cash commission of $27,414.72 and a total of 102,805 compensation warrants. The compensation warrants have substantially the same terms as the warrants but are not transferable.

The shares, the warrants and the compensation warrants are subject to a hold period expiring Oct. 19, 2018. The financing remains subject to final acceptance of the TSX Venture Exchange.

About CVR Medical Corp.

CVR Medical is a company that is involved in an equal parts joint venture with CVR Global Inc. The joint venture operates in the medical industry focused on the commercialization of a proprietary subsonic, infrasonic and low-frequency sound wave analysis technology and has patents to a diagnostic device designed to detect and measure carotid arterial stenosis.

We seek Safe Harbor.